☰

Mark A. Castanares, Ph.D. - Publications

Affiliations: 
2012 Johns Hopkins University, Baltimore, MD 
Area:
Pharmacology, Radiology, Oncology
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Wu W, Donoho G, Iversen P, Dempsey J, Capen A, Castanares M, Stephens J, Boehnke K, Reinhard CR, Lin A. Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models Cancer Research. 79: 3508-3508. DOI: 10.1158/1538-7445.Am2019-3508  0.379
2018 Wu W, King C, Donoho G, Iversen P, Capen A, Castanares M, Stephens J, Ding Y, Pratt S, Martinez R, Buchanan S, Reinhard C, Beckmann R, Lin A. Abstract 336: Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models Cancer Research. 78: 336-336. DOI: 10.1158/1538-7445.Am2018-336  0.342
2015 Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA. Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. The Prostate. PMID 26499105 DOI: 10.1002/Pros.23115  0.526
2015 Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWEese TL, Lupold SE. Systemic administration and targeted radiosensitization via chemically synthetic aptamer-siRNA chimeras in human tumor xenografts. Molecular Cancer Therapeutics. PMID 26438155 DOI: 10.1158/1535-7163.Mct-15-0291-T  0.395
2015 Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R. Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 771-80. PMID 25501577 DOI: 10.1158/1078-0432.Ccr-14-0891  0.603
2014 Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG. Evaluation of prostate-specific membrane antigen as an imaging reporter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 805-11. PMID 24700883 DOI: 10.2967/Jnumed.113.134031  0.539
2013 Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Pomper MG, Rodriguez R. Abstract 3919: A preclinical model of laparoscopy demonstrating the feasibility of detecting PSMA positive cells with a NIR fluorophore (YC-27): implications for strategies to decrease positive margins during prostatectomy. Cancer Research. 73: 3919-3919. DOI: 10.1158/1538-7445.Am2013-3919  0.52
2013 Neuman B, Eifler J, Castanares M, Chowdhury W, Chen Y, Pomper M, Rodriguez R. 1319 A NEAR-INFRARED IMAGING AGENT IDENTIFIES PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITIVE CELLS DURING LAPAROSCOPIC SURGERY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2673  0.544
2011 Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: Clinical applications and promising new horizons Current Medicinal Chemistry. 18: 4206-4214. PMID 21838685 DOI: 10.2174/092986711797189600  0.309
2011 Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. The Journal of Clinical Investigation. 121: 2383-90. PMID 21555850 DOI: 10.1172/Jci45109  0.465
2011 Ni X, Zhang Y, Ribas J, Chodhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Abstract 5387: Prostate-targeted radiosensitization via aptamer-shRNA chimeras Cancer Research. 71: 5387-5387. DOI: 10.1158/1538-7445.Am2011-5387  0.422
2011 Eifler J, Chowdhury W, Castanares M, Foss C, George N, Pomper M, Rodriguez R. V1221 INTRAOPERATIVE USE OF A PROSTATE SPECIFIC MEMBRANE ANTIGEN-BASED FLUORESCENT IMAGING AGENT FOR PROSTATE CANCER IN A MOUSE MODEL Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.879  0.584
2011 Eifler J, Chowdhury W, Foss C, Castanares M, Chen Y, George N, Pomper M, Rodriguez R. 1623 A FLUORESCENT IMAGING AGENT SPECIFICALLY TARGET PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1731  0.561
2010 Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R. Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses Cancer Gene Therapy. 17: 585-597. PMID 20448671 DOI: 10.1038/Cgt.2010.15  0.427
2008 Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry. 51: 7933-43. PMID 19053825 DOI: 10.1021/Jm801055H  0.554
2008 Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: Structural characterization Journal of Medicinal Chemistry. 51: 7737-7743. PMID 19053759 DOI: 10.1021/Jm800765E  0.451
2008 Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) Journal of Medicinal Chemistry. 51: 4504-4517. PMID 18637669 DOI: 10.1021/Jm800111U  0.561
Show low-probability matches.